@Bgheyath#ANOCA#INOCA has two phenotypes.
Microvascular dysfunction and coronary vasospasms.
There are important differences in the treatment options and symptoms of vasospastic and microvascular angina.
Session Four of #INOCA2025 looks at how we can build better services and diagnostics for #ANOCA patients.
Talks include:
- Patient Stories
- Setting Up a Service – Dr. Mark Mariathas, Dr. Tusha Kotecha
- Non-Invasive Diagnostics: CMR – Prof. Amedeo Chiribiri
- PET, Echo Doppler, and ETT – Prof. Eva Prescott
Real-world strategies for expanding access to #CMD care.
https://t.co/mw5GlWRCmF
#INOCA2025 #CMR #ServiceDesign #CardiologyInnovation
BANCC are pleased to invite you to register for our upcoming webinar 'Angina/Ischemia with Non-Obstructive Coronary Arteries (ANOCA & INOCA) – how to assess, treatment options and the patient perspective' on Wednesday, 15 October 2025 19:00 - 20:20.
https://t.co/BrdaSrnPbC
🔊2 weeks to go to INOCA 2025!
📍London SE1 7AR
@TheBHF@NIHRresearch
Incredible international faculty
How to sessions
Guideline updates
Informative talks
Debates
Live cases
Lived experience
Innovations in INOCA
‼️Register ASAP
https://t.co/UjWmimT9K9
' ANOCA progressed from the initial scepticism of the scientific community regarding its existence to the demonstration of its clinical relevance and the need for a standardized diagnostic algorithm (as recommended in current ESC Guidelines)'
https://t.co/6HXMWsd5MA
Everything you wanted to know about INOCA in 2 days! Well worth registering asap for #INOCA2025, a @TheBHF - @NIHRresearch CV partnership meeting. Stellar international faculty, guideline updates, how to sessions, debates, breaking research, discussion, live cases and more!
Persistent angina following PCI. Comprehensive coronary function testing is a valuable tool in diagnosing the underlying cause in patients with no residual CAD @ved5688#ANOCA#cardiotwitter#AHAJournals https://t.co/5SV3S61lYQ
Four years in the making, we’re finally here. Congratulations to our colleagues Peter Damman & team for their 1st patient in #iCorMicA! Thank you for the hospitality and cath lab tips. Fantastic team and beautiful campus at Radboud UMC Nijmegen. It was an absolute delight. #INOCA
We are delighted to announce our first educational and Q&A session about Patient and Public Involvement in Research!
➡️Have a question or topic you’d like covered? Let us know and register here by 24th June: https://t.co/13OVJ20AIk
More info: [email protected]
Thank you to everyone who passed on the details of our survey.
CONGRATULATIONS to all who took Survey 1! You are, in part, going to the ESC (European Society of Cardiology) Congress with Sarena La on August 29th in Madrid.
@sarena_la
https://t.co/QgnunjeuO4
Congratulation to Her Heart Australia on their 10year Anniversary Event in Melbourne. Our Co Founder Cindy McCall was honored to be on a panel sharing her experiences, creating awareness of what heart disease truly looks like.
Bravo @Heartspasms1 finally meets
@RosannaTavella
Happy Nurse’s Week!
Thank you to all the nurses who advocate for patients and watch out for them in vulnerable moments! They are the backbone of our care.
While the umbrella term #ANOCA is useful, it's important to determine whether a person's symptoms are due to microvascular dysfunction, microvessel or coronary artery vasospasms.
@drruthannharpur Why?
Some women would prefer to be able to give their own paracetamol or ibuprofen, it would avoid any delays in receiving pain relief.
Perhaps women should be given the choice?
The WARRIOR trial was ambitious, but without endotyping, outcomes didn’t change.
Dr. Jay Widmer (@DrArgyle) explains why individualized testing is critical for advancing care in INOCA.
🎥 Full breakdown now on YouTube! https://t.co/OoPwqJK61G
#Cardiology#ACC2025#CathLab
#WARRI❤️R @ACC2025
2476 ♀ pts w/ INOCA, intensive medical rx vs usual care:
❌ Didnt reduce MACE by 20% at 5y fu
🚨Cautious interpretation of results: insufficient adherence, power
⛔️ Do NOT d/c statins and ACEi/ARB
‼️Additional data are needed in this growing pt population
WARRIOR: Hear From Elizabeth Dineen, DO, FACC, on the WARRIOR trial from #ACC25 which found that intensive medical therapy did 🚫 significantly impact the rate of serious CV events at 5️⃣ years in women w/ suspected INOCA.
🔗 Watch on #ACCAnywhere TV: https://t.co/M3c9zTEVlB